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doi:10.1Objective:Massive perioperative blood product transfusion may be required with thoracic aortic operations and
is associated with poor outcomes. We analyzed independent predictors of massive transfusion in thoracic aortic
surgical patients undergoing deep hypothermic circulatory arrest.
Methods: The study consisted of 168 consecutive patients undergoing open thoracic aortic procedures involving
deep hypothermic circulatory arrest between July 2005 and August 2008. We identified 26 preoperative and pro-
cedural variables as potentially related to blood product use, tested for association with total blood products
transfused by multivariate linear regression model, and constructed logistic regression model for massive trans-
fusion (requiring 5 units of transfused packed red blood cells between incision and 48 postoperative hours).
Results:Multivariate linear regression determined that 6 significant variables accounted for 42% of variation in
total blood products transfused: age (P ¼ .008), preoperative hemoglobin (P ¼ .04), weight (P ¼ .02), cardio-
pulmonary bypass time (P<.0001), emergency status (P<.0001), and resternotomy (P<.0001). Final predic-
tive logistic regression model included 1-g/dL increase in preoperative hemoglobin (odds ratio, 0.54; 95%
confidence interval, 0.43–0.69; P<.0001), 10-minute increase in cardiopulmonary bypass time (odds ratio,
1.15; 95% confidence interval, 1.05–1.26; P¼ .0026), and emergency status (odds ratio, 4.02; 95% confidence
interval, 1.53–10.55; P ¼ .0047.
Conclusions: Cardiopulmonary bypass time, emergency status, and preoperative hemoglobin were independent
predictors of massive transfusion. These variables, along with weight, age, and resternotomy, were associated
with total blood product use in thoracic aortic operations involving deep hypothermic circulatory arrest.
(J Thorac Cardiovasc Surg 2011;141:1283-8)Massive perioperative transfusion may occur with thoracic
aortic operations. Although there is certainly no substitute
for meticulous surgical technique, the etiology of unusu-
ally high transfusion requirement is often multifactorial.
Hemostatic derangements in aortic surgery are caused by
a multitude of interrelated factors, including interference
with the vascular integrity, surgical dissection, deep hypo-
thermic circulatory arrest (DHCA), ischemia and reperfu-
sion, dilution of coagulation factors from large-volume
fluid resuscitation, transient need for heparinization, and
the use of cardiopulmonary bypass (CPB).1 Patient-level
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Mbin, platelets, prothrombin time, and partial thromboplas-
tin time.2-4
There are few clinical data addressing predictors of
massive transfusion specific to operations for disease of
the thoracic aorta, particularly those involving DHCA.5,6
The DHCA used for neuroprotection in thoracic aortic
surgery slows coagulation cascade activity, reduces
coagulation factor synthesis, increases fibrinolysis,
decreases platelet count, and impairs platelet function.7
The prosthetic grafts used for aortic repair consume platelets
and other factors.8 Aortic disease itself may also predispose
toward coagulopathy through the exposure of tissue factor
and other mechanisms.9,10
Adverse outcomes attributable to the sequelae of massive
perioperative transfusion are well recognized in the cardiac
surgical literature, including a strong independent associa-
tion with mortality.11,12 Identification of patients at high
risk for requiring massive transfusion not only will allow
improved risk stratification and preoperative counseling
but also may create an opportunity for therapeutic
modalities targeted toward individual patients in the
perioperative period. Our objective was to determine the
predictors of massive perioperative transfusion with
open thoracic aortic procedures involving DHCA. We
therefore tested the hypothesis that patient and proceduraldiovascular Surgery c Volume 141, Number 5 1283
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
DHCA ¼ deep hypothermic circulatory arrest
IQR ¼ interquartile range
PRBCs ¼ packed red blood cells
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Mcharacteristics could be used to model the need for
transfusion with thoracic aortic surgery.MATERIALS AND METHODS
Data Source
The Duke Thoracic Aortic Surgery Database is a prospectively main-
tained, comprehensive clinical registry of all patients who have undergone
any thoracic aortic procedure at Duke University Medical Center (Durham,
NC) since 2005. This study included all patients who underwent a thoracic
aortic procedure with DHCA between July 2005 and August 2008, exclud-
ing only patients who underwent a separate procedure in the perioperative
period that resulted in massive transfusion. All procedures were performed
by a single surgeon (G.C.H.), thus minimizing the contribution of variation
in surgical technique to the findings. This study was approved by the Duke
University institutional review board, which waived the need for individual
patient consent. The Duke Thoracic Aortic Surgery Database provided
baseline characteristics, clinical variables, and surgical procedure details.
Review of individual medical records was undertaken to complete any
missing clinical data points, and blood bank records provided precise infor-
mation regarding amounts of blood products administered.Conduct of Procedures and Anesthesia
Nonpulsatile CPB was conducted for each case with a membrane oxy-
genator after a crystalloid andmannitol prime andwith an arterial line filter.
Porcine heparin was administered as a bolus of 300 U/kg and supplemented
to maintain an activated clotting time longer than 480 seconds. A 5000-unit
bolus of heparin was given before circulatory arrest. During CPB,
temperature-adjusted flow rates of 2.5 L/(min $ m2) were used, and mean
arterial pressure was generally maintained between 50 and 70 mm Hg. An-
esthesia was maintained with isoflurane (0.5%–1.0%) by the oxygenator.
Alpha stat management was used for maintenance of normal pH, PO2, and
PCO2 values. Antegrade and retrograde cold blood cardioplegic solutions
were used for myocardial protection. Our institutional preference is to per-
form open thoracoabdominal (extent I–III) and descending aortic aneurysm
repairs with DHCA.
Before the portion of the aortic reconstruction requiring DHCA, the pa-
tient was cooled on CPB until electrocerebral inactivity was detected by
electroencephalography by previously described techniques13; electrocere-
bral inactivity was usually reached at a nasopharyngeal temperature be-
tween 14C and 18C. Once electrocerebral inactivity was achieved
through hypothermia, the circulation was stopped. Antegrade cerebral per-
fusion (5–15 mL/[kg $min]) was typically used for adjunct cerebral perfu-
sion during the period of systemic DHCA. After aortic reconstruction, CPB
was reinstituted, and the patient was gradually rewarmed to a normal tem-
perature after a 5-minute period of cold reperfusion for free radical wash-
out. Four units of fresh-frozen plasma were typically added to the circuit to
ensure adequate anticoagulant factors during DHCA. A hematocrit of 0.18
to 0.20 was generally acceptable during CPB, although this was increased
to more than 0.20 for separation from CPB. Protamine sulfate was admin-
istered after separation from CPB to reverse heparin anticoagulation until
the activated clotting time returned to baseline or the ratio of 1 mg to
100 units of heparin was reached. We maintained a general approach of1284 The Journal of Thoracic and Cardiovascular Suravoiding unnecessary use of blood products, which were not administered
unless bleeding or anemia was observed. After separation from CPB, red
blood cells were transfused according to the patient’s preoperative condi-
tion, volume status, and hemoglobin concentration.
Standard practice included intraoperative administration of an antifi-
brinolytic therapy. Before its withdrawal from the US market, aprotinin
(Bayer Corporation, West Haven, Conn) was used (2-MKIU bolus and
0.5-MKIU/h infusion until bleeding cessation). Subsequently, e-amino-
caproic acid was administered as a 10-g bolus followed by a 1-g/h infu-
sion, with an additional 5-g bolus before separation from CPB to account
for that lost during hemofiltration, which was performed in all cases to
remove excess crystalloid before separation from CPB. The return of
washed, shed red blood cells (BRAT II blood cell salvage machine;
Cobe Cardiovascular Inc, Arvada, Colo) to the patient was routine. Trans-
fusion decisions in the perioperative period were aided by local guide-
lines and use of chest tube output, activated clotting time, platelet
count, fibrinogen level, thromboelastography, prothrombin time, and par-
tial thromboplastin time, as recommended by the American Society of
Anesthesiologists published guidelines.14 Clopidogrel and other P2Y12
inhibitors, regardless of dose, were withheld 7 days before the operation.
Aspirin (325 mg) was withheld 5 days before the operation. Aspirin
(81 mg) was not withheld before the operation. All antiplatelet agents
were restarted at preoperative dosages on postoperative day 1 unless
active bleeding was present.
Outcome Measures
The 26 candidate variables for the analysis included age, sex, race,
American Society of Anesthesiologists grade, diabetes, preoperative cre-
atinine level, warfarin (Coumadin) use, partial thromboplastin time, plate-
let count, international normalized ratio, hemoglobin concentration,
weight, height, body surface area, blood pressure, aprotinin use, previous
cardiac surgical procedure, emergency status, concomitant cardiac proce-
dure, total arch versus hemiarch repair, thoracoabdominal aortic aneu-
rysm type, aortic crossclamp time, cerebral circulatory arrest time
(period when brain was receiving less than 100% of normal cerebral
blood flow, including antegrade or retrograde cerebral perfusion), sys-
temic circulatory arrest time (period during which lower body was not
perfused, longer than cerebral circulatory arrest time for total arch re-
placement and open descending or thoracoabdominal aortic repairs and
equal to cerebral circulatory arrest time for hemiarch repairs), and CPB
time. Allogeneic blood product use included all products given from
the time of incision through postoperative days 0, 1, and 2, including
any given at the time of return to the operating room for bleeding. Volume
of intraoperative blood cell salvage machine transfusion was not included
in this calculation, because this blood is not allogeneic. Considering the
need for massive transfusion as a dichotomous outcome, we used a previ-
ously described definition of massive transfusion.11 Patients who received
at least 5 units of packed red blood cells (PRBCs) were defined as having
had massive transfusion.
Statistical Analysis
Patient and operative characteristics are summarized according to pres-
ence or absence of massive transfusion. Table 1 presents categoric vari-
ables as percentages; continuous variables are presented as mean  SD
unless otherwise stated. For comparisons, the Wilcoxon rank sum test
was used for continuous variables, and the c2 test was used for categoric
variables, with an alternative hypothesis that the rates across columns
were not equal.
We evaluated the association of patient and procedural characteristics
with the need for transfusion in 2 ways. Primarily, a linear regressionmodel
was developed with total blood products transfused as the outcome vari-
able. Total blood products included all allogeneic products from the case
start time through 48 postoperative hours. Because blood product use
was not normally distributed, a log transform was performed beforegery c May 2011
TABLE 1. Patient characteristics and operative variables
Characteristic Overall (n ¼ 168) MT (n ¼ 49) No MT (n ¼ 119) P value
Age (y) 57.4  14.2 60.6  15.5 56.1  13.4 .06
Female 29% (49) 38% (18) 25% (30) .09
Nonwhite 6% (10) 9% (4) 5% (6) .27
American Society of Anesthesiologists grade 3.5  0.5 3.8  0.4 3.4  0.5 < .0001
Diabetes 3% (5) 4% (2) 2% (3) .66
Preoperative creatinine (mg/dL) 1.3  1.3 1.6  1.8 1.2  0.9 .11
Preoperative warfarin 16% (26) 20% (10) 14% (16) .31
Preoperative partial thromboplastin time (s) 32.6  9.6 31.5  9.6 33.1  9.7 .32
Preoperative platelets (109 cells/L) 214.6  58.1 216.1  62.2 213.9  56.5 .82
Preoperative international normalized ratio 1.05  0.16 1.12  0.26 1.03  0.09 .001
Preoperative hemoglobin (g/dL) 13.5  2.0 12.0  2.1 14.1  1.7 < .0001
Weight (kg) 83.3  18.9 78.6  16.4 85.3  19.6 .03
Height (cm) 174.7  11.2 172.0  12.7 175.8  10.4 .07
Body surface area (m2) 1.98  0.24 1.91  0.23 2.01  0.25 .01
Total blood products (units, median
with 25th75th percentile)
13 (8–20) 22 (18–31) 9 (6–13) < .0001
Recombinant factor VIIa 3% (5) 10% (5) 0% (0) < .0001
Aprotinin 48% (81) 48% (24) 48% (57) .97
Maximum aortic diameter (cm) 5.85  1.01 6.04  1.19 5.77  0.92 .14
Reoperation (resternotomy) 27% (45) 39% (21) 21% (24) .01
Emergency status 24% (40) 39% (20) 17% (20) .001
Crossclamp time (min) 136.9  51.1 142.2  57.3 136.6  48.2 .38
Cerebral circulatory arrest time (min) 22.2  7.4 24.6  7.4 21.1  7.1 .004
Systemic circulatory arrest time (min) 28.0  19.6 34.8  19.6 25.1  17.4 .001
Cardiopulmonary bypass time (min) 225.8  60.5 248.7  85.8 216.1  42.3 .01
Concomitant procedure 22% (36) 34% (17) 16% (19) .007
Location of aortic repair .004
Root or ascending only 1.2% (2) 2% (1) 0.8% (1)
Arch involvement 89% (150) 82% (40) 92% (110)
Total arch 9.5% (16) 16% (8) 6.7% (8)
Descending or thoracoabdominal 10% (16) 20% (10) 5% (6)
Blood cell salvage device volume (mL) 537  475 715  663 464  351 .01
12-h chest tube drainage (mL) 664  568 1050  864 517  341 .0003
Taken back to operating room for bleeding 6% (10) 18.4% (9) 0.84% (1) < .0001
30-d Mortality 3.0% (5) 4.1% (2) 2.5% (3) .09
Categoric data are given as percentages, with the number of patients in parentheses and continuous data as mean  SD, except as noted. MT, Massive transfusion.
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Manalysis. Secondarily, we developed a logistic regression model for mas-
sive transfusion (5 units of PRBCs) as a dichotomous outcome.
We identified 26 preoperative and procedural variables as being poten-
tially related to blood product use. Univariate associations were assessed
with 1-way analysis of variance for categoric variables and correlation tests
for continuous variables. Race was defined as white versus nonwhite. Of
the 26 variables, 16 had P values lower than .05 when testing for a differ-
ence between the groups. These 16 variables were included in a backward
stepwise procedure that eliminated nonsignificant variables individually
until only significant variables remained. In this manner, a final predictive
model was developed. To create the linear regressionmodels for total blood
products and CPB time, linear univariate association tests were used, with
nonsignificant variables dropped from the multivariate model 1 at a time
until only significant variables remained in the model.
Finally, with Pearson correlation coefficients, we conducted a post hoc
assessment of the relationship of blood product transfusion with other met-
rics of perioperative bleeding by examining correlations with volume of
processed blood (blood cell salvage machine) returned to the patient intra-
operatively and chest tube drainage from time of intensive care unit arrival
to 12 postoperative hours. We also evaluated the proportion of total blood
products given during CPB to distinguish between anemia during CPB andThe Journal of Thoracic and Carcontinued bleeding after CPB as reasons for requiring transfusion. All sta-
tistical analyses were performed with SAS statistical software version 9.1.3
(SAS Institute Inc, Cary, NC).
RESULTS
Patient and Operative Variables
One hundred seventy thoracic aortic procedures with
DHCA were performed during the period of study. Only
two patients were excluded, both of whom had major blood
loss and massive transfusion from another procedure in the
perioperative period. Thus 168 thoracic aortic procedures
were available for data abstraction and fulfilled selection cri-
teria, representing a single-center, single-surgeon experience.
Figure 1 displays the use of the various blood products in
the 168 study patients, with medians as well as upper and
lower quartiles for PRBCs (median, 3 units; interquartile
range [IQR], 1–6 units), platelets (3 units; IQR, 2–4 units),
cryoprecipitate (0 units; IQR, 0–1 units), fresh-frozendiovascular Surgery c Volume 141, Number 5 1285
FIGURE 1. Blood products transfused. Note that y-axis values represent
units of blood products, with total representing total units transfused. Cryo-
precipitate is not included in graphic display becausemedian number of units
transfused was zero overall. PRBC, Packed red blood cells: FFP, fresh-
frozen plasma; Non-MT, no massive transfusion; MT, massive transfusion.
TABLE 2. Multivariate linear regression model for log-transformed
total blood products
Variable Regression slope P value
Age 0.009 .008
Preoperative hemoglobin 0.05 .04
Weight 0.006 .02
Cardiopulmonary bypass time 0.004 <.0001
Emergency status 0.52 <.0001
Reoperation 0.47 <.0001
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Mplasma (6 units; IQR, 4–10 units), and total blood products
transfused (13 units; IQR, 8–20 units). We classified 49 pa-
tients (29%) as having massive transfusion if they received
at least 5 units of transfused PRBCs. The remaining 119 pa-
tients were classified as not receiving massive transfusion.
Table 1 describes patient and operative variables of the
cohort and details a univariate comparison of characteristics
from the massive transfusion and no massive transfusion
groups. Of note, recombinant activated factor VII (NovoS-
even; Novo Nordisk Inc, Princeton, NJ) was given to only 5
patients, all of whom had received massive transfusion
(10% of this cohort). Uses of the pharmacologic agents
Coumadin (preoperatively, 20% vs 14%, P ¼ .31) and
aprotinin (intraoperatively, 48.0% vs 48.4%, P ¼ 0.97)
were similar between the groups. Among the 40 emergency
cases, none of the patients were taking clopidogrel preoper-
atively, and only 1 was taking aspirin at 325 mg (aspirin at
81 mg is not withheld before elective cases).
Overall, the type of aortic repair was root or ascending
only in 1.2% (2% massive transfusion vs 0.8% no massive
transfusion), hemiarch or total arch in 89% (82% massive
transfusion vs 92% no massive transfusion), with 9.5% be-
ing total arch (16% massive transfusion vs 6.7% no mas-
sive transfusion), and descending or thoracoabdominal in
10% (20% massive transfusion vs 5% no massive transfu-
sion). The procedure was classified as resternotomy (reop-
eration) for 39% of the massive transfusion group,
compared with 21% of the no massive transfusion group
(P ¼ .01); there were no reoperative descending or thora-
coabdominal aortic aneurysm procedures. Patients with
massive transfusion were also more likely to undergo con-
comitant procedures (34% vs 16%, P ¼ .001) and more
likely to have had emergency operations (39% vs 17%,
P ¼ .001). The thirty-six cases with concomitant proce-
dures included coronary artery bypass grafting (n ¼ 24,
67%), maze (n ¼ 3, 8%), atrial septal defect repair
(n ¼ 3, 8%), and other (n ¼ 6, 16%). The indication for
emergency operation was acute type A aortic dissection in
all cases. Aortic crossclamp times were equivalent between1286 The Journal of Thoracic and Cardiovascular Surthe groups (142 vs 137 minutes, P¼ .38), whereas systemic
circulatory arrest time (35 vs 25 minutes, P ¼ .001) and
CPB time (249 vs 216 minutes, P¼ .007) were significantly
longer in the massive transfusion group.
Outcome Metrics
Return to the operating room for bleeding was required in
6% of cases. The return rate for bleeding among themassive
transfusion groupwas 18%, versus 0.8% among the nomas-
sive transfusion group (P<.0001). Of note, mean blood cell
salvage machine volumes returned to patients intraopera-
tively were 715 mL in the massive transfusion group and
464 mL in the no massive transfusion group (P ¼ .01), and
mean 12-hour chest tube drainage volumes were 1050 mL
in the massive transfusion group and 517 mL in the no mas-
sive transfusion group (P¼ .0003). Mortality at 30 days was
3% overall and was higher in the massive transfusion group
(4%) than in the no massive transfusion group (2.5%).
The Pearson correlation coefficients were 0.43
(P ¼ 0.001) between total blood products transfused and
volume of salvaged blood cells returned intraoperatively
and 0.54 (P< .0001) between total blood products trans-
fused and 12-hour chest tube drainage, while blood cell sal-
vage machine volume and chest tube drainage had no
association (r ¼ 0.049, P ¼ .55). The mean PRBC volume
given during CPB was 1.3  2.1 units (range, 0–16 units),
compared with 3.9  4.7 PRBC units (range, 0–26 units)
given from procedure start time to 48 postoperative hours.
Multivariate Models and Predictors
The correlation coefficient for PRBC and total blood
product transfusion was greater than 0.90, with total blood
products used as the primary, continuous outcome variable.
The linear regression model is described in Table 2, with
6 significant variables independently associated with total
blood product transfusion: age (P ¼ .008), preoperative
hemoglobin (P ¼ .04), weight (P ¼ .02), CPB time
(P<.0001), emergency status (P<.0001), and reoperation
status (P<.0001). The adjusted R2 for this model was 0.42,
indicating that these variables accounted for 42% of the
variability in blood products transfused.
The logistic regression model for the outcome massive
transfusion is shown in Table 3. The odds ratios for the out-
come ofmassive transfusion are as follows: for every 1-g/dLgery c May 2011
TABLE 3. Predictors of massive transfusion (logistic regression
model)
Variable
Odds
ratio
95%Wald
confidence
interval
Predictor
P value
Preoperative hemoglobin
(per 1-g/dL increment)
0.543 0.428–0.688 <.0001
Cardiopulmonary bypass
time (per 10-min increase)
1.15 1.05–1.26 .0026
Emergency status 4.02 1.532–10.553 .0047
Williams et al Perioperative Managementincrease in preoperative hemoglobin, odds ratio was 0.54
(95% confidence interval, 0.43–0.69; P<.0001); for every
10-minute increase in CPB time, odds ratio was 1.15 (95%
confidence interval, 1.05–1.26; P ¼ .0026); and for emer-
gency status, odds ratio was 4.02 (95% confidence interval,
1.53–10.55; P¼ .0047). Many procedural factors correlated
with CPB time and therefore were not independent predic-
tors of bleeding. These included crossclamp time, body sur-
face area, concomitant procedure, and reoperation. The
univariate associations with massive transfusion are be
noted in Table 1. A multivariable regression analysis pre-
dicting CPB time (R2 for the model of 0.26) showed that
increased body surface area, concomitant procedure, and
reoperation were all significant predictors (Table 4).
DISCUSSION
In this observational study of consecutive patients under-
going thoracic aortic procedures involving DHCA from
2005 through 2008, we were able to identify the patient
and procedural characteristics associated both with overall
blood product use and with massive transfusion. First, inde-
pendent predictors of total blood products transfused in-
cluded age, preoperative hemoglobin, weight, CPB time,
and emergency status. Second, a logistic regression model
determined massive perioperative transfusion to be inde-
pendently predicted by 3 variables: preoperative hemoglo-
bin level, CPB time, and emergency operation status.
An initial descriptive analysis of patient variables found
that patients in the massive transfusion group tended to be
older, smaller (lower preoperative weight and body surface
area), and sicker (higher American Society of Anesthesiol-
ogists grade, lower preoperative hematocrit). Durations of
CPB and of both systemic and cerebral circulatory arrest
were longer for the massive transfusion group. Many of
the variables showed expected univariate associations withTABLE 4. Predictors of cardiopulmonary bypass time (linear
regression model)
Variable
Regression
slope SE t Value P value
Body surface area 49.56 16.85 2.94 .0037
Concomitant procedure 53.70 10.24 5.24 <.0001
Reoperation 35.30 9.766 3.61 .0004
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Mblood product use, but collinearity of variables confounded
persistence of independent association in a multivariate
model. For example, although it was an independent predic-
tor in the linear regression model, reoperation did not re-
main so in the final logistic regression model because it
did not independently contribute to the model of massive
transfusion more than did CPB time alone.
CPB time and emergency operation are recognized predic-
tors of transfusion,2,3,5 and the time required to achieve
DHCA further prolongs CPB time, likely causing platelet
and enzyme dysfunction.1,3,7 The value of preoperative
anemia as a prognosticator for adverse outcomes has been
replicated by several groups11,15-17; however, previous
studies have not examined anemia in a model for
transfusion requirement in thoracic aortic surgery with
DHCA. In our patient sample, hemoglobin may be a marker
of broader physiologic reserve and consumption of platelets
and coagulation factors by various aortic pathologies.
Several limitations should be considered when interpreting
the findings of this study. First, this was a retrospective, obser-
vational study, for which causality cannot be inferred. The ef-
fects of unknown or unmeasured confounders on the observed
associations cannot be excluded. A major limitation of other
studies investigating predictors of perioperative blood loss
in cardiac surgery has been that the investigations compared
cases across different surgical, anesthesia, and intensive
care unit teams, resulting in wide, unadjusted variation in
surgical practices and perioperative management strate-
gies.2,3,18 We reduced but did not eliminate surgical
technique and institutional practice as confounders by
reporting a large series of patients undergoing aortic surgery
with DHCA conducted by a single surgeon and postsurgical
care unit with a protocol-driven approach to transfusion.
Although this study represents the largest to date examin-
ing factors associated with transfusion in the DHCA popula-
tion, a relatively large number of variables were determined
a priori to be of clinical importance in considering predictors
ofmassive transfusion,which increases the chanceof a type II
error. We chose not to use a principal components strategy to
reduce the degrees of freedomby combining potential predic-
tors because of the resulting inability to interpret individual
coefficients. Also of note, a systematic change in the pharma-
cologic management of bleeding occurred during the study
period. When aprotinin was officially removed from the
US market in late 2007, patients received e-aminocaproic
acid as an alternative agent, although aprotinin use was sim-
ilar between those with and without massive transfusion.
This analysis did not discriminate between transfusion to
treat anemia and that to treat bleeding. This could be re-
garded as a weakness or a strength of the design; we elected
to evaluate overall transfusion requirements, because delete-
rious effects of transfusion are related to the total number of
units transfused. For the same reason, we extended our out-
come to transfusion in the perioperative period, rather thandiovascular Surgery c Volume 141, Number 5 1287
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correlation between units of PRBCs transfused and both in-
traoperative bleeding (blood cell salvage machine volume
transfused) and postoperative bleeding (chest tube drainage),
approximately a third of the PRBC units transfused were
given before separation from CPB to treat preexisting ane-
mia, acute blood loss before CPB, or hemodilution during
CPB. Intraoperative transfusions before closure of the chest
have been excluded by other investigators on the basis of the
premise that excessive bleeding during this part of the oper-
ation frequently reflects inadequate surgical hemostasis and
may not reflect the hemostatic defect induced by CPB.2,3
Although deposition of platelets and circulating blood
proteins, as well as nonsurgical bleeding related to graft
porosity and needle hole injury, occur less with the
polyethylene terephthalate (Dacron) graft material used in
our series than with polytetrafluoroethylene and other graft
materials, however, these interactions remain an important
consideration.19 The use of large prosthetic vascular con-
duits andDHCA is unique to aortic surgery and has an imme-
diate effect on the coagulation cascade, which would be lost
to analysis without inclusion of intraoperative transfusions
and the volume of salvaged blood cells returned intraopera-
tively, correlated closely with total blood product use.
Our model for predicting massive perioperative transfusion
may allow more focused use of both established and novel
strategies for reducing perioperative blood loss, including
correction of hypothermia and perioperative pharmacologic
interventions available for reducing the coagulation dysfunc-
tion associated with CPB and aortic surgery.20,21 Typical
pharmacologic interventions have focused on antifibrinolytic
agents but could also focus on intraoperative adjuncts for the
prevention of platelet dysfunction7,22 or the promotion of
hemostasis with fibrinogen concentrate21 or recombinant fac-
tor VII.23 The etiology of preoperative anemia in patients un-
dergoing elective cardiac operations has been described, and it
is suggested that in most cases the anemia is preventable.24
Specifically, diagnosis of chronic anemia and its correction
through iron supplementation or erythropoietin25 for elective
cases is worth investigating with further clinical studies.
CONCLUSIONS
Our data support a model of CPB time, emergency status,
and preoperative hemoglobin as independent predictors of
massive perioperative transfusion in thoracic aortic proce-
dures involving DHCA. This finding creates an opportunity
for clinical investigations directed toward targeted thera-
peutic maneuvers for high-risk patients.
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